Efficacy and Safety of Evogliptin Add-on Therapy to Dapagliflozin/Metformin Combinations in Patients with Poorly Controlled Type 2 Diabetes Mellitus: A 24-Week Multicenter Randomized Placebo-Controlled Parallel-Design Phase-3 Trial with a 28-Week Extension

Autor: Jun Sung Moon, Il Rae Park, Hae Jin Kim, Choon Hee Chung, Kyu Chang Won, Kyung Ah Han, Cheol-Young Park, Jong Chul Won, Dong Jun Kim, Gwan Pyo Koh, Eun Sook Kim, Jae Myung Yu, Eun-Gyoung Hong, Chang Beom Lee, Kun-Ho Yoon

Publikováno v: Diabetes & Metabolism Journal, Vol 47, Iss 6, Pp 808-817 (2023)

Background This study investigates the long-term efficacy and safety of evogliptin add-on therapy in patients with inadequately controlled type 2 diabetes mellitus (T2DM) previously received dapagliflozin and metformin (DAPA/MET) combination. Methods

Externí odkaz: https://doaj.org/article/eab3181c0ab14508823de9a37c7683d8

Tento výsledek nelze pro nepřihlášené uživatele zobrazit.
K zobrazení výsledku je třeba se přihlásit.

Correction: Phase-3 trial of recombinant human alkaline phosphatase for patients with sepsis-associated acute kidney injury (REVIVAL).

Autor: Pickkers P; Department of Intensive Care, Radboudumc, Nijmegen, The Netherlands. Peter.Pickkers@radboudumc.nl., Angus DC; Department of Critical Care Medicine, University of Pittsburgh School of Medicine, Pittsburgh, PA, USA., Bass K; AM-Pharma, Utrecht, The Netherlands., Bellomo R; Department of Intensive Care, Austin Hospital, Melbourne, VIC, Australia.; Australian and New Zealand Intensive Care Research Centre, Monash University, Melbourne, VIC, Australia., van den Berg E; AM-Pharma, Utrecht, The Netherlands., Bernholz J; AM-Pharma, Utrecht, The Netherlands., Bestle MH; Department of Anesthesiology and Intensive Care, Copenhagen University Hospital-North Zealand, Hilleroed, Denmark.; Department of Clinical Medicine, University of Copenhagen, Copenhagen, Denmark., Doi K; Department of Emergency and Critical Care Medicine, The University of Tokyo, Tokyo, Japan., Doig CJ; Department of Critical Care Medicine, Medicine and Community Health Sciences, Cumming School of Medicine, University of Calgary, Calgary, Canada., Ferrer R; Department of Intensive Care Medicine, SODIR-VHIR Research Group, Val d'Hebron University Hospital, Barcelona, Spain., Francois B; Intensive Care, Inserm CIC 1435 & UMR 1092, CHU Limoges, Limoges, France., Gammelager H; Department of Intensive Care Medicine, Aarhus University Hospital, Aarhus, Denmark., Pedersen UG; Intensive Care Unit, Zealand University Hospital, Koege, Denmark., Hoste E; Department of Internal Medicine and Pediatrics, Intensive Care Unit, Ghent University Hospital, Ghent University, Ghent, Belgium.; Research Foundation-Flanders, (FWO), Brussels, Belgium., Iversen S; Department of Anaesthesiology and Intensive Care, Slagelse Hospital, Slagelse, Denmark., Joannidis M; Division of Intensive Care and Emergency Medicine, Department of Internal Medicine, Medical University of Innsbruck, Innsbruck, Austria., Kellum JA; Center for Critical Care Nephrology, Department of Critical Care Medicine, University of Pittsburgh, Pittsburgh, USA., Liu K; Division of Nephrology, Department of Medicine, University of California, San Francisco, San Francisco, CA, USA., Meersch M; Department of Anesthesiology, Intensive Care and Pain Medicine, University Hospital Münster, Münster, Germany., Mehta R; Department of Medicine, University of California San Diego, La Jolla, CA, USA., Millington S; University of Ottawa/The Ottawa Hospital, Ottawa, Canada., Murray PT; School of Medicine, University College Dublin, Dublin, Ireland., Nichol A; Australian and New Zealand Intensive Care Research Centre, Monash University, Melbourne, VIC, Australia.; University College Dublin-Clinical Research Centre at St Vincent's University Hospital, Dublin, Ireland., Ostermann M; Department of Critical Care, Guys & St Thomas' Foundation Trust, London, UK., Pettilä V; Department of Perioperative and Intensive Care, University of Helsinki and Helsinki University Hospital, HUS, Helsinki, Finland., Solling C; Department of Anaestesiology and Intensive Care, Viborg Regional Hospital, Viborg, Denmark., Winkel M; AM-Pharma, Utrecht, The Netherlands., Young PJ; Australian and New Zealand Intensive Care Research Centre, Monash University, Melbourne, VIC, Australia.; Intensive Care Unit, Wellington Hospital, Wellington, New Zealand.; Medical Research Institute of New Zealand, Wellington, New Zealand.; Department of Critical Care, University of Melbourne, Melbourne, VIC, Australia., Zarbock A; Department of Anesthesiology, Intensive Care and Pain Medicine, University Hospital Münster, Münster, Germany.

Publikováno v: Intensive care medicine [Intensive Care Med] 2024 Apr; Vol. 50 (4), pp. 614-615.

52727 Efficacy and Safety of Sarecycline in Chinese Patients with Acne Vulgaris: A Randomized, Multicenter, Double-Blind, Placebo-Controlled, Phase-3 Trial.

Autor: Baykal, Tolga, Chen, Xue, Zhang, Jianzhong, Robles, Judit Cabedo, Kostov, Belchin, Gil, Esther Garcia

Publikováno v: Journal of the American Academy of Dermatology; 2024 Supplement, Vol. 91 Issue 3, pAB195-AB195, 1p

Azacitidine Post-Remission Therapy for Elderly Patients with AML: A Randomized Phase-3 Trial (QoLESS AZA-AMLE)

Autor: Esther Natalie Oliva, Anna Candoni, Prassede Salutari, Giuseppe A. Palumbo, Gianluigi Reda, Giuseppe Iannì, Giovanni Tripepi, Maria Cuzzola, Debora Capelli, Corrado Mammì, Caterina Alati, Maria Concetta Cannatà, Pasquale Niscola, Bianca Serio, Pellegrino Musto, Ernesto Vigna, Antonio Volpe, Lorella Maria Antonia Melillo, Maria Teresa Arcadi, Donato Mannina, Maria Elena Zannier, Roberto Latagliata

Publikováno v: Cancers; Volume 15; Issue 9; Pages: 2441

This phase-3 randomized multicenter trial evaluated the efficacy of subcutaneous azacitidine (AZA) post-remission therapy vs. best supportive care (BSC) in elderly acute myeloid leukemia (AML) patients. The primary endpoint was the difference in dise

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::1f77fcfc1a67ce9c82176703385230f7
https://hdl.handle.net/20.500.11769/558189